spacer
home > ebr > spring 2002 > a record-breaking us$27 billion of biotech deals supports strong pharma m&a activity in 2001
PUBLICATIONS
European Biopharmaceutical Review

A Record-Breaking US$27 Billion of Biotech Deals Supports Strong Pharma M&A Activity in 2001

The value of pharmaceutical mergers and acquisitions (M&A) in 2001 almost doubled to US$61 billion from US$34 billion in 2000 (excluding the US$76 billion formation that year of GlaxoSmithKline), bucking the significant downward trend witnessed in most other sectors. The number of deals remained stable at 334 in 2001, compared with 341 in 2000. In a period where most industries have experienced at least a 25 per cent downturn in M&A activity, the pharmaceutical sector has maintained its deal-making momentum. The aggregate value of deals is down because 2001 witnessed no mega-mergers to rival the prior year combination of Glaxo Wellcome and SmithKline Beecham. But with Amgen's US$17 billion bid for Immunex, plus a further US$10 billion of biotech deals in 2001, the foundations are being laid for a Big Biotech sector that will increasingly compete with Big Pharma.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Neal Ransome, Partner at PricewaterhouseCoopers Corporate Finance

Neal Ransome is European leader of PricewaterhouseCoopers' Pharmaceuticals and Healthcare Corporate Finance team. He has over 10 years' experience of corporate finance transactions, and has been focusing on the pharma and health care sectors since 1997. Neal's clients in the sector have included large pharmacos such as GlaxoSmithKline and Aventis, emerging companies such as Powderject and a wide range of smaller clients in the health care and biotech sectors.
Neal has also acted for a large number of private equity clients in the sector, including 3i, Warburg Pincus and Mercury. The European team which he leads comprises approximately 20 professional staff, located in all key financial centres, and combines corporate finance experts with recruits from the industry.

spacer
Neal Ransome
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ADM Supports Clinical Trial into Effects of Probiotic Supplements for COVID-19 Patients in Hospital Care

ADM and Hospital de Sagunto, one of the largest medical centers in the Valencia region, today announce their partnership for a clinical trial into the effects of using a food supplement containing live microbial strains to promote gut microbiome balance and help improve health functions related to outcomes for COVID-19 patients in high-risk groups. On 18th March Dr Xavier Cortés, gastroenterologist at Hospital de Sagunto, communicated with medical staff in China who had observed that many COVID-19 patients had exhibited abnormal changes in their gut microbiome.
More info >>

White Papers

e-tools enhance clinical trial performance

e-novex

In today’s ever-evolving medical business, technological changes require innovation to meet growing market demands and to bring about advances in the industry. One such development currently taking place in the field of clinical research is how e-tools are initiating a boost in the productivity of clinical trials.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement